PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)
Retrieved on:
화요일, 4월 12, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Company, Private Securities Litigation Reform Act, Cancer, Pharmacy, Synthetic, Journal, PRTC, BUP, Therapy, U.S. FDA, Control, Multimedia, Fat, Patient, Liver, Research, SEC, Frontiers Media, Risk, Environment, Platform supply vessel, Monash University, Monash Institute of Medical Research, University of Melbourne, Pain management, Chem, Allopregnanolone, Lymphatic system, Immune system, Technology, Biology, Twitter, LSE, Brain, Chemistry, Degenerative disease, Journal of Controlled Release, Prodrug, BIG, Annual report, FDA, PureTech Health, Buprenorphine, Axis, Pharmaceutical industry, Trevaskis, Glyph, Pharmacology, Frontiers
View the full release here: https://www.businesswire.com/news/home/20220411005986/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20220411005986/en/
PureTech announced the publication of preclinical proof-of-concept showing up to 20-fold oral bioavailability enhancement by the Glyph platform of buprenorphine, a clinically-validated opioid replacement therapy. - Results from this study further amplify the breadth of the Glyph delivery technology and its ability to use new chemistry and molecules for versatile applications.
- The Glyph technology generates novel orally dosed prodrugs by reversibly linking small molecule drugs to dietary fat molecules.
- PureTechs LYT-300 is the first therapeutic candidate generated by the Glyph technology platform to enter the clinic.